Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Volume: 381, Issue: 4, Pages: 338 - 348
Published: Jul 25, 2019
Abstract
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1–4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR...
Paper Details
Title
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Published Date
Jul 25, 2019
Volume
381
Issue
4
Pages
338 - 348
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History